I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial.

@article{Herstein2005I125VP,
  title={I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial.},
  author={Andrew Herstein and Kent Wallner and Gregory Merrick and Hiroki Mitsuyama and Julius Armstrong and Lawrence D. True and William A Cavanagh and Wayne Butler},
  journal={Cancer journal},
  year={2005},
  volume={11 5},
  pages={
          385-9
        }
}
BACKGROUND We tested the hypothesis that the shorter half-life of Pd-103 versus I-125 results in different late radiation-related morbidities following prostate brachytherapy. METHODS As of June 14th, 2002, 352 of a planned total of 600 patients with 1997 American Joint Committee on Cancer (AJCC) clinical stage T1c-T2a prostatic carcinoma (Gleason grade 2-6, PSA 4-10 ng/mL) had been randomized to implantation with I-125 (144 Gy, TG-43) or Pd-103 (125 Gy, NIST-99). Treatment-related morbidity… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 21 CITATIONS

External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer.

  • International braz j urol : official journal of the Brazilian Society of Urology
  • 2014
VIEW 1 EXCERPT
CITES BACKGROUND